Related references
Note: Only part of the references are listed.Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs
Vittorio Montefusco et al.
HAEMATOLOGICA (2020)
A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome
Meral Beksac et al.
HAEMATOLOGICA (2020)
Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
Nico Gagelmann et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs
Lohith Gowda et al.
BONE MARROW TRANSPLANTATION (2019)
Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents
Roberto Mina et al.
CANCER (2019)
Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients
Artur Jurczyszyn et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis
Marjorie Pick et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT
Nico Gagelmann et al.
HAEMATOLOGICA (2018)
Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
Meletios Dimopoulos et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcome
Chezi Ganzel et al.
LEUKEMIA RESEARCH (2018)
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group
Eirini Katodritou et al.
BLOOD CANCER JOURNAL (2018)
Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT
Nico Gagelmann et al.
HAEMATOLOGICA (2018)
The Mutational Landscape of Primary Plasma Cell Leukemia
Carolina D. Schinke et al.
BLOOD (2018)
The possible role of burden of therapy on the risk of myeloma extramedullary spread
Silvia Mangiacavalli et al.
ANNALS OF HEMATOLOGY (2017)
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
W-J Chng et al.
LEUKEMIA (2017)
Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study
Philippe Moreau et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group
Michele Cavo et al.
LANCET ONCOLOGY (2017)
Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
L. Rasche et al.
NATURE COMMUNICATIONS (2017)
Current applications of multiparameter flow cytometry in plasma cell disorders
T. Jelinek et al.
BLOOD CANCER JOURNAL (2017)
Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing
Michele Moschetta et al.
CURRENT OSTEOPOROSIS REPORTS (2017)
Distinct Clinical Outcomes between Paramedullary and Extramedullary Lesions in Newly Diagnosed Multiple Myeloma
Khishigjargal Batsukh et al.
IMMUNE NETWORK (2017)
Multiple myeloma with extramedullary disease: impact of autologous stem cell transplantation on outcome
L. Kumar et al.
BONE MARROW TRANSPLANTATION (2017)
Evolutionary biology of high-risk multiple myeloma
Charlotte Pawlyn et al.
NATURE REVIEWS CANCER (2017)
Carfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement
Ignacio Espanol et al.
CLINICAL CASE REPORTS (2017)
Marizomib for central nervous system-multiple myeloma
Ashraf Badros et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Primary Plasma Cell Leukemia in the Era of Novel Agents: A Multicenter Study of the Japanese Society of Myeloma
Hirono Iriuchishima et al.
ACTA HAEMATOLOGICA (2016)
Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study
Eli Muchtar et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice
Artur Jurczyszyn et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
Saad Z. Usmani et al.
BLOOD (2016)
Myelomatous Involvement of the Central Nervous System
Jonas Paludo et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2016)
Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myelome
Bruno Royer et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Primary plasma cell leukemia 2.0: advances in biology and clinical management
Antonino Neri et al.
EXPERT REVIEW OF HEMATOLOGY (2016)
Comparison of intramedullary myeloma and corresponding extramedullary soft tissue plasmacytomas using genetic mutational panel analyses
S. J. de Haart et al.
BLOOD CANCER JOURNAL (2016)
Identification of Phenotype Profile Related to the Extramedullary Involvement in Multiple Myeloma Relapse
Lucie Rihova et al.
BLOOD (2016)
Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience
Eirini Katodritou et al.
ANNALS OF HEMATOLOGY (2015)
Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation
Mathew Weinstock et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations
Cindy Varga et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Features of Extramedullary Disease of Multiple Myeloma: High Frequency of P53 Deletion and Poor Survival: A Retrospective Single-Center Study of 834 Cases
Shuhui Deng et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Plasma cell leukemia: from biology to treatment
Tomas Jelinek et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2015)
Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns
Ingrid Cifola et al.
ONCOTARGET (2015)
CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation
Aldo M. Roccaro et al.
CELL REPORTS (2015)
Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy
George Mulligan et al.
BLOOD (2014)
Trends in survival of patients with primary plasma cell leukemia: a population-based analysis
Wilson I. Gonsalves et al.
BLOOD (2014)
Patterns of Central Nervous System Involvement in Relapsed and Refractory Multiple Myeloma
Al-ola Abdallah et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2014)
Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse
Ludek Pour et al.
HAEMATOLOGICA (2014)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2014)
Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients
A. K. Nooka et al.
LEUKEMIA (2014)
Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia
P. Musto et al.
LEUKEMIA (2014)
Central nervous system multiple myeloma - potential roles for intrathecal therapy and measurement of cerebrospinal fluid light chains
Denise Lee et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Cytogenetics of extramedullary manifestations in multiple myeloma
Lisa Billecke et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents
Christine I. Chen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease
Jan B. Egan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Lenalidomide Is Effective for the Treatment of Bortezomib-Resistant Extramedullary Disease in Patients With Multiple Myeloma: Report of 2 Cases
Chisako Ito et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2013)
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
C. Fernandez de Larrea et al.
LEUKEMIA (2013)
Effective treatment of pomalidomide in central nervous system myelomatosis
Alberto Mussetti et al.
LEUKEMIA & LYMPHOMA (2013)
Lenalidomide is active for extramedullary disease in refractory multiple myeloma
Tomonori Nakazato et al.
ANNALS OF HEMATOLOGY (2012)
Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases
Leo Rasche et al.
ANNALS OF HEMATOLOGY (2012)
P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment
Abdel Kareem Azab et al.
BLOOD (2012)
Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features
Abdel Kareem Azab et al.
BLOOD (2012)
Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: A retrospective survey of 50 patients
Alessandro Gozzetti et al.
CANCER (2012)
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents
Saad Z. Usmani et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research
A. Mahindra et al.
LEUKEMIA (2012)
Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols
S. Z. Usmani et al.
LEUKEMIA (2012)
Expression levels of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and focal adhesion kinase in patients with multiple myeloma and their relationship to clinical stage and extramedullary infiltration
Su-Yun Wang et al.
LEUKEMIA & LYMPHOMA (2012)
The genetic architecture of multiple myeloma
Gareth J. Morgan et al.
NATURE REVIEWS CANCER (2012)
Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?
Herve Avet-Loiseau et al.
BLOOD (2011)
Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach
Joan Blade et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma
K. Detweiler Short et al.
LEUKEMIA (2011)
Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients
M. Varettoni et al.
ANNALS OF ONCOLOGY (2010)
P53 deletion may drive the clinical evolution and treatment response in multiple myeloma
Lucia Lopez-Anglada et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Primary plasma cell leukemia and autologous stem cell transplantation
Mary B. Drake et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
RADIOTHERAPY FOR EXTRAMEDULLARY PLASMACYTOMA OF THE HEAD AND NECK
Kimberly M. Creach et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2009)
Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia
Hong Chang et al.
LEUKEMIA RESEARCH (2009)
p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma
Neil Sheth et al.
LEUKEMIA RESEARCH (2009)
Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome
M. C. Minnema et al.
BONE MARROW TRANSPLANTATION (2008)
Genetic aberrations and survival in plasma cell leukemia
R. E. Tiedemann et al.
LEUKEMIA (2008)
Extravasation and homing mechanisms in multiple myeloma
Isabelle Vande Broek et al.
CLINICAL & EXPERIMENTAL METASTASIS (2008)
Bortezomib and extramedullary disease in multiple myeloma: The shine and dark side of the moon
Ridvan Ali et al.
LEUKEMIA RESEARCH (2007)
Extramedullary disease and targeted therapies for hematological malignancies - is the association real?
P. Raanani et al.
ANNALS OF ONCOLOGY (2007)
Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains
Mark A. Dawson et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2007)
Bortezomib:: an effective agent in extramedullary disease in multiple myeloma
R Laura et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2006)
Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients
JA Pérez-Simón et al.
LEUKEMIA (2006)
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
PL Bergsagel et al.
BLOOD (2005)
Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients
JJ Keats et al.
BLOOD (2005)
The absence of CD56 on malignant plasma cells in the cerebrospinal fluid is the hallmark of multiple myeloma involving central nervous system
H Chang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome
R Zeiser et al.
BONE MARROW TRANSPLANTATION (2004)
Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions
H Chang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma
CV Hedvat et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Can thalidomide be effective to treat plasma cell leptomeningeal infiltration?
P Vicari et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2003)
Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma
IMS Dahl et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Thalidomide is effective for extramedullary relapse of multiple myeloma postallogeneic bone marrow transplantation
JJ Biagi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
A coordinated change in chemokine responsiveness guides plasma cell movements
DC Hargreaves et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Thalidomide in multiple myeloma:: lack of response of soft-tissue plasmacytomas
J Bladé et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis
S Bezieau et al.
HUMAN MUTATION (2001)
Share Paper
